Loading
A phase 2 trial of irinotecan (and liposomal irinotecan) and bevacizumab (glioblastoma use) in colorectal cancer, run by University of Wisconsin, Madison, now recruiting.
Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer is a phase 2, interventional study registered as NCT05854498 by University of Wisconsin, Madison, with a registry enrolment figure of 50 participants, started 2023-10-13 and due to reach its primary completion in 2028-09. Interventions recorded: Liposomal irinotecan; TAS102; Bevacizumab. Conditions listed: Metastatic Colorectal Cancer. Primary outcome: Progression Free Survival (PFS). Colorectal eligibility wording from the registry: "* Patients must have a histologically or cytologically confirmed diagnosis of colorectal adenocarcinoma and be metastatic or unresectable". Sites: United States. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Irinotecan (and liposomal irinotecan), Bevacizumab (glioblastoma use), Topoisomerase-I inhibitors (and ADC payloads), Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.
Shares Irinotecan (and liposomal irinotecan), Bevacizumab (glioblastoma use), Topoisomerase-I inhibitors (and ADC payloads), Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.
Shares Irinotecan (and liposomal irinotecan), Bevacizumab (glioblastoma use), Topoisomerase-I inhibitors (and ADC payloads), Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.
Shares Irinotecan (and liposomal irinotecan), Bevacizumab (glioblastoma use), Topoisomerase-I inhibitors (and ADC payloads), Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.
Shares Irinotecan (and liposomal irinotecan), Topoisomerase-I inhibitors (and ADC payloads), Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), Topoisomerase-I inhibitors (and ADC payloads), Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/